Navigation Links
Drugs of Abuse Confirmation/Quantitation-Cannabinoids (9-carboxy-THC)-Serum or Plasma

ProductsDrugs of Abuse Confirmation/Quantitation-Cannabinoids (9-carboxy-THC)-Serum or Plasma
Company ARUP Laboratories
Item Drugs of Abuse Confirmation/Quantitation-Cannabinoids (9-carboxy-THC)-Serum or Plasma
Features 
Description ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories' clients include more than half of the nation's university teaching hospitals and children's hospitals, major commercial laboratories, military and government facilities, and major clinics.
Info ARUP Laboratories
Customer Service: (800) 522-2787
Web site: http://www.aruplab.com

Related medicine products :

1. Triage® Drugs of Abuse Panels
2. Drugs of Abuse Urine Screen Control
3. Drugs of Abuse Array Cocaine Metabolite Assay
4. Drugs of Abuse Array Evidence Opiates Assay
5. Drugs of Abuse Array Evidence Methodone Assay
6. Drugs of Abuse Array Evidence Ampphetimine Assay
7. Drugs of Abuse Array Evidence Barbiturates Assay
8. Drugs of Abuse Array Evidence Ampphetimine
9. Drugs of Abuse Array Evidence Cannabiniods Assay
10. Drugs of Abuse Array Evidence Phencyclidine Assay
11. Drugs of Abuse Array Evidence Benzodiazpine Class Assay
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products:
(Date:9/23/2014)... Dallas, Texas (PRWEB) September 23, 2014 ... Gunn Finance Tough Mudder team just completed the ... class obstacle course event that helps fund the wounded ... Finance Tough Mudder team member, the ”Tough Mudder is ... military-style obstacle course. Designed and created by British Special ...
(Date:9/23/2014)... University of Cambridge has found that a common characteristic of ... ,signature, in the brain. The results are published today (23 ... The researchers studied 80 adult men with autism: 38 who ... found that language delay was associated with differences in brain ... lobe, insula, ventral basal ganglia, which were all smaller in ...
(Date:9/23/2014)... Published by Nationwide Lifts, the book is designed ... of their mobility in a new way, using equipment that ... lifts are that equipment and can bring mobility and ... elevator business, I’ve seen so many people struggle with ... one with mobility issues,” said Andy Darnley, co-founder and president ...
(Date:9/23/2014)... a popular supplier of wedding dresses and special occasion gowns ... marine ball dresses . Along with this, the firm has ... items; all of them are now provided with deep discounts, ... has won more than 2000 happy customers in the global ... and after-sale services. The company is offering thousands of graceful ...
(Date:9/22/2014)... Recently, BamboofloorChina.com, an outstanding online supplier ... solid bamboo floors . According to the company’s ... at discounted rates, up to 30 percent off. The ... , BamboofloorChina.com is good at making ... are made according to the newest customer feedback. A ...
Breaking Medicine News(10 mins):Health News:Presence or absence of early language delay alters anatomy of the brain in autism 2Health News:Nationwide Lifts, America’s Leader in Home Elevators, Is Proud to Announce the Release of Its First Book, “Stair Lifts: Move Up, Not Out!” 2Health News:Fashionable Marine Ball Dresses Added To BuyTopDress.com’s Collection 2Health News:Cheap Solid Bamboo Floors From Outstanding Online Supplier BamboofloorChina.com 2
... Geneva, Switzerland, Friday, 25 June 2010: Today, world renowned ... latest trends in treatment and cutting edge research in ... hepatocellular carcinoma (HCC) the third most common cause ... of death among patients with liver cirrhosis. ...
... By Ellin Holohan HealthDay Reporter , FRIDAY, ... from chronic migraine headaches feel more rejected, ridiculed, and ... other neurological troubles, a new study contends. And ... victims experience, the Philadelphia researchers say. Lead author ...
... ... Prefer Use of Blood Tests, including QuantiFERON®-TB, to Diagnose Tuberculosis Infection in Certain Populations ... Valencia, CA ... Prevention (CDC) issued new and important guidelines on the detection of Mycobacterium tuberculosis infections, ...
... THURSDAY, June 24 (HealthDay News) -- A new drug, the ... people with type 2 diabetes who are already taking the ... helped patients lose weight, is novel in that it does ... a study appearing in the June 26 issue of ...
... ... Climate Savers Computing Initiative, a non-profit organization dedicated to reducing computer power consumption by 50 ... ... joined the Climate Savers Computing Initiative, a non-profit organization dedicated to reducing computer power consumption ...
... ... with a new technology that the skin care industry has pursued for years: enhanced ... ... new technology that the skin care industry has pursued for years: enhanced absorption. ...
Cached Medicine News:Health News:International liver cancer congress provides possible solutions to reduce significant burden 2Health News:International liver cancer congress provides possible solutions to reduce significant burden 3Health News:For Migraine Sufferers, Stigma Adds to Burden 2Health News:For Migraine Sufferers, Stigma Adds to Burden 3Health News:TB Claims One Life Every 17 Seconds; Almost Two Million People Each Year 2Health News:TB Claims One Life Every 17 Seconds; Almost Two Million People Each Year 3Health News:Drug Helps Tackle Type 2 Diabetes in New Way, Study Says 2Health News:Drug Helps Tackle Type 2 Diabetes in New Way, Study Says 3Health News:Be Green Canada Joins Computing Initiative 2Health News:Be Green Canada Joins Computing Initiative 3Health News:New Anti-Aging Skin Care Line Promotes Penetration 2
(Date:9/22/2014)... Sept. 22, 2014 Children,s National Health ... Sept. 29 at 5 p.m. EDT for its ... in response to continued strong interest from inventors.  ... will be awarded to the winning presentations at ... Symposium hosted by Children,s National in October. For ...
(Date:9/22/2014)... BROOK, N.J. , Sept. 22, 2014 /PRNewswire/ ... antibody therapies to treat infectious disease, today announced ... volunteer safety studies of obiltoxaximab (ETI-204). Obiltoxaximab is ... inhalational anthrax and data from these studies support ... administered intravenously (IV) at the intended therapeutic dose. ...
(Date:9/22/2014)... and SHANGHAI , ... Group (BHG), a global knowledge leader in healthcare ... partnership to support healthcare innovation in ... personal connected health technologies. Continua and BHG announced ... Forum being held this week in ...
Breaking Medicine Technology:Calling all medical innovators: Submit your pediatric medical device pitch for Children's National competition by Sept. 29 2Calling all medical innovators: Submit your pediatric medical device pitch for Children's National competition by Sept. 29 3Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 2Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 3Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 4Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 5Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 6Continua and Borderless Healthcare Group Form Strategic Partnership, Launch the Healthcare Technology Innovation Center in Shanghai 2Continua and Borderless Healthcare Group Form Strategic Partnership, Launch the Healthcare Technology Innovation Center in Shanghai 3Continua and Borderless Healthcare Group Form Strategic Partnership, Launch the Healthcare Technology Innovation Center in Shanghai 4